Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right here
They bought a copper unit for 8 million back in may and many people saw projected earnings to sky rocket which they are starting to do on pure fundamentals.....read this
http://seekingalpha.com/article/206541-t...
This guy might of called the shot heard around the investing community.
Its not a penny stock,but if you have college tuition money to come up with in the next year?
TIII IS A BUY AND HOLD
(TIII) is a stock to invest,Not trade
It will help fund my kids college tuition
People,I hope you have buy orders(pre-market) in for jan 04?
This is the hidden gem,and SUSMOOSE will be legend,LOL
Maybe? d.d tells me this.Maybe someone in my life will believe me for once!
Oh well don't chase buy now,I guess
When he speaks I LISTEN!
Long Tiii
Its game over IMO people.
Take your losses,I guess
It over
Ameritrade shows last trade 71000 at 0.05
runs?
your kidding right?
we are about to hit an all time low
OMG,SOMETHING BAD IS HAPPENING
ARE WE GOING TO ZERO?
PPS IS ACTING LIKE A COMPANY ABOUT TO FOLD
IM SCARED
This is the most pathetic stock i've ever owned
Huge volume again today,looks good guys.
What a joke and a waste of eye sight watching this junk!
LOOK AT ALL THE MINING STOCKS TODAY
SHZ,XING,THEY ARE ALL FLYING REALLY HIGH
WE ARE STUCK IN A SCAM,I FEEL WORTHLESS
As soon as I saw that P.R for a second unsolicited bid
I knew I was done.
Thats what raised the red flags,heck I even joked around and posted third bid no wait,4 bid.
Looking back now it was not a joke,losing my money should not be joked with.
Anyway it sucks
Is This True?
Don't tell me........
Bio.Org/News
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec 26, 2010 1:45 EST - Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced today that it has suspended the Investigational New Drug (IND) Application study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).The company would not say as to why the trial is being suspeneded but did say that a more detailed press release will be sent in the near future.
ANYBODY WATCHING ACTC?
I think news is about to hit ACTC!
I BUYING MORE $$$$$$$$$
imo of course
but look at the facts!
Anybody buy (actc)?,wow nice momentum happening!
Strong buy
Holy Smokes, $$$$$$ actc $$$$$$
is runnung hard
susmoose Share Thursday, December 16, 2010 11:03:30 AM
Re: None Post # of 366034
UPDATE 1-Discovery Labs says drug likely to get FDA nod
Wed Dec 16,2011 11:00EST Discovery Laboratories, Inc.
DSCO.O
$0.19
+0.02+10.74%
Discovery Labs, commented, "We are pleased with the guidance received and outcomes obtained from our interaction with the FDA. This guidance provides a viable option for Surfaxin and meaningfully supports advancing our pipeline initiatives to potentially address a broad range of respiratory diseases such as RDS, Acute Respiratory Failure, Acute Lung Injury and Cystic Fibrosis. We look forward to continued productive dialogue with the FDA.
"Our most advanced programs from our KL4 surfactant pipeline, Surfaxin, Surfaxin LS(TM) and Aerosurf(R), have the potential to greatly improve the management of RDS and to redefine the RDS market. Our top priority is to secure strategic alliance partners and access capital to advance our pipeline and build shareholder value. As we move forward, we will take into account further interaction with the FDA and make strategic assessment, together with existing and potential new partners to determine the appropriate level and timing of Surfaxin investment and to maximize the value of our KL4 pipeline for RDS."
Accordingly, Discovery Labs initiated a series of side-by-side studies employing both the preterm lamb model of RDS and the BAT and believes that the correlated results demonstrate comparability and support approval of Surfaxin.
Our goal as a company is to bring life changes into the medical community,and to bring profitabilty back to our shareholders. Rating :
UPDATE 1-Discovery Labs says drug likely to get FDA nod
Wed Dec 16,2011 11:00EST Discovery Laboratories, Inc.
DSCO.O
$0.19
+0.02+10.74%
Discovery Labs, commented, "We are pleased with the guidance received and outcomes obtained from our interaction with the FDA. This guidance provides a viable option for Surfaxin and meaningfully supports advancing our pipeline initiatives to potentially address a broad range of respiratory diseases such as RDS, Acute Respiratory Failure, Acute Lung Injury and Cystic Fibrosis. We look forward to continued productive dialogue with the FDA.
"Our most advanced programs from our KL4 surfactant pipeline, Surfaxin, Surfaxin LS(TM) and Aerosurf(R), have the potential to greatly improve the management of RDS and to redefine the RDS market. Our top priority is to secure strategic alliance partners and access capital to advance our pipeline and build shareholder value. As we move forward, we will take into account further interaction with the FDA and make strategic assessment, together with existing and potential new partners to determine the appropriate level and timing of Surfaxin investment and to maximize the value of our KL4 pipeline for RDS."
Accordingly, Discovery Labs initiated a series of side-by-side studies employing both the preterm lamb model of RDS and the BAT and believes that the correlated results demonstrate comparability and support approval of Surfaxin.
Our goal as a company is to bring life changes into the medical community,and to bring profitabilty back to our shareholders. Rating :
DSCO IS READY TO BLOW!!!!!!!!!!!!
ON HIGH VOLUME FOLKS!
I POSTED THE NEWS ALL MORNING
REAL MONEY ABOUT TO ENTER!
DSCO ABOUT TO BREAKOUT FOLKS!
NEWS! NICE PLAY FOR TODAY!
More News On Dsco,Wow!
http://www.themarketfinancial.com/discov...
Discovery Laboratories (NASDAQ:DSCO), often compared to the likes of Cell Therapeutics (NASDAQ:CTIC), Arena (NASDAQ:ARNA), Dendreon (NASDAQ:DNDN), and OREX (NASDAQ:OREX) saw its shares rise more than 8.52% on Tuesday’s trading, making it one of the highest gainers on any major exchange for the day. The excitement comes following growing anticipation that they will file a request for hearing to maintain its listing on the NASDAQ exchange sooner rather than later, as well as move one step closer to its NDA resubmission of its flagship product, Surfaxin, during 1st quarter of 2011. It is important to note that the FDA granted Discovery Labs Orphan Drug designation for Surfaxin for the treatment of RDS in premature infants, and the EMEA granted Discovery Labs Orphan Drug designation for Surfaxin for the prevention and treatment of RDS in premature infants. An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.
Several sources have also indicated that a short squeeze could be taking place ahead of the pending catalyst. The company has more than 7.35 million shares short out of a total 158 million float, and of these the shorts have roughly seven days to cover.
FDA Timeline
Surfaxin, a synthetic peptide-containing lung surfactant, completed re-validation of Biological Activity Test (BAT) for quality control and stability in May 2010. Then, it was submitted via protocol to FDA which was a completed required preclinical program with written guidance from FDA that was received in June 2010. If approved, Surfaxin would be the first synthetic, peptide-containing surfactant for commercial use in neonatal medicine.
Dr. Russell Clayton, Vice President, Research and Development, Preclinical and Regulatory Affairs commented, “Discovery’s plan for the potential approval of Surfaxin continues to benefit from the FDA’s direction and their recent suggestions have been incorporated into our plan. Another positive aspect of the most recent communication is the FDA’s indicated willingness to continue to interact on our approach to gain potential Surfaxin approval.”
Positive Clinical Trials
For further details please click on the link above.
DSCO running hard in pre-market!
On big news
DSCO RUNNING PRE-MARKET!
WARRINGTON, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS).
http://www.thestreet.com/story/10948755/...
Good luck Longs!
WARRINGTON, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS).
http://www.thestreet.com/story/10948755/...
Hot of the press!
WARRINGTON, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS).
http://www.thestreet.com/story/10948755/...
UPDATE 1-Discovery Labs says drug likely to get FDA nod
Wed Dec 15,2011 1:39pm
Discovery Laboratories, Inc.
DSCO.O
$0.19
+0.02+10.74%
Discovery Labs, commented, "We are pleased with the guidance received and outcomes obtained from our interaction with the FDA. This guidance provides a viable option for Surfaxin and meaningfully supports advancing our pipeline initiatives to potentially address a broad range of respiratory diseases such as RDS, Acute Respiratory Failure, Acute Lung Injury and Cystic Fibrosis. We look forward to continued productive dialogue with the FDA.
"Our most advanced programs from our KL4 surfactant pipeline, Surfaxin, Surfaxin LS(TM) and Aerosurf(R), have the potential to greatly improve the management of RDS and to redefine the RDS market. Our top priority is to secure strategic alliance partners and access capital to advance our pipeline and build shareholder value. As we move forward, we will take into account further interaction with the FDA and make strategic assessment, together with existing and potential new partners to determine the appropriate level and timing of Surfaxin investment and to maximize the value of our KL4 pipeline for RDS."
Accordingly, Discovery Labs initiated a series of side-by-side studies employing both the preterm lamb model of RDS and the BAT and believes that the correlated results demonstrate comparability and support approval of Surfaxin.
Our goal as a company is to bring life changes into the medical community,and to bring profitabilty back to our shareholders.
BUYOUT ...........WHOLE SMOLY!
New store will not be open until mid 2011.......WOW!
Due to consumer spending and marketing conditions.
More dilution until then
Stragey is correct .........LOL
0.0019 IS COMING
This guy is a real piece of work
OUR HARD EARNED MONEY AT RISK FOR THE NEW STORE THAT WS SUPPOSED TO BE OPEN NOW!!!!!!!!!!!!!!!!!
BANKRUPTCY!
See you in your new business adventure in CANADA,DANNY!
WOW,YOUR ONE SLICK CANADIAN!
Its Over!
Danny Alex will soon release the news
LOL...
IM selling this garbage.
BRAVADA IS A COMPLETE NOBODY!
AND SO WILL BE YOUR ACCOUNT
BELIEVE ME
That's JIM CRAMMER'S company that's making that prediction on (dsco) today! wow!
http://www.thestreet.com/story/10946852/2/15-biotech-stock-predictions-for-2011.html
That's jIM CRAMMER'S company that put this out today on $$ DSCO! $$
http://www.thestreet.com/story/10946852/2/15-biotech-stock-predictions-for-2011.html
THE STREET.COM PUT THIS PREDICTION OUT TODAY PEOPLE ON (DSCO) UP UP AND AWAY!!!!!!!!!!
http://www.thestreet.com/story/10946852/2/15-biotech-stock-predictions-for-2011.html
THE STREET.COM PUT THIS PREDICTION OUT TODAY ON $$ DSCO $$
http://www.thestreet.com/story/10946852/2/15-biotech-stock-predictions-for-2011.html
HOT OFF THE PRESS! {AEN}Adeona and Meda AB to Partner On Fibromyalgia Drug
Featured In: Manufacturing & Capabilities | Newsletter | Outsourcing News
Wednesday,Dec 15,2010
Adeona Pharmaceuticals, Inc., has entered into a corporate partnership with Sweden-based Meda AB, to develop flupirtine for the treatment of fibromyalgia syndrome which contemplates the payment to Adeona of up to $17.5 million in upfront and milestone payments, plus royalties.
Under the terms of the agreement, Adeona has granted Meda an exclusive sublicense to all of Adeona's patents covering the use of flupirtine for fibromyalgia. These patents have issued in the US and are pending in Canada and Japan (the "Territory"). Meda will assume all future development costs for the commercialization of flupirtine for fibromyalgia. Adeona received an up-front payment of $2.5 million and is entitled to milestone payments of $5 million upon filing of a New Drug Application with the Food and Drug Administration for flupirtine for fibromyalgia and $10 million upon marketing approval. Adeona is also entitled to receive royalties of 7% of net sales of flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the Territory. Adeona will share such royalties equally with Adeona's university licensor.
(AEN) awaiting phase2 results $$$$$$$$$$$$$$
any minute or hour!
(AEN) AWAITING RESULTS,ANY MINUTE,MIGHT GET HALTED
___________ PROOF OF THE FRAUD _________
http://geomininternational.com/index.php